Skip to main content

Advertisement

SpringerLink
Log in

Pancreatic cancer

Next-generation algorithms for neoantigen selection

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

Predicting clinical outcomes in cancer using neoantigen burden is imperfect because current algorithms use only the binding affinity of putative neoantigens to HLA. A new study models pancreatic tumour response through a deeper understanding of tumour immunology, providing new tools for identifying neoantigens and characteristics that define their quality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Tumour evolution in response to immune pressure in pancreatic cancer.

References

  1. Mehnert, J. M. et al. The challenge for development of valuable immuno-oncology biomarkers. Clin. Cancer Res. 23, 4970–4979 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).

    Article  CAS  PubMed  Google Scholar 

  4. Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature http://dx.doi.org/10.1038/nature24462, (2017).

  5. Zitvogel, L., Ayyoub, M., Routy, B. & Kroemer, G. Microbiome and anticancer immunosurveillance. Cell 165, 276–287 (2016).

    Article  CAS  PubMed  Google Scholar 

  6. Chekmasova, A. A. et al. Successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res. 16, 3594–3606 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, 21231, Maryland, USA

    Alexander Hopkins & Elizabeth Jaffee

Authors
  1. Alexander Hopkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth Jaffee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth Jaffee.

Ethics declarations

Competing interests

E.J. has the potential to receive royalties from Aduro Biotech for vaccines developed in her laboratory.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hopkins, A., Jaffee, E. Next-generation algorithms for neoantigen selection. Nat Rev Gastroenterol Hepatol 15, 135–136 (2018). https://doi.org/10.1038/nrgastro.2017.184

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2017.184

  • Springer Nature Limited

Search

Navigation